Skip to content

Outcome of allergen specific immunotherapy in asthmatic children

Long-term clinical and immunological effect of sublingual and subcutaneous immunotherapy in dust mite allergic asthma/rhinitis children: 3 years prospective randomized controlled trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612000555853
Enrollment
50
Registered
2012-05-25
Start date
2007-03-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

randomized controlled open trial of children with mild persistant asthma, HDM sensitized were included. All evaluated at baseline 1st and 3rd years with clinical status, bronchial hyperreactivity and immunological parameters

Interventions

1. sublingual immunotherapy (SLIT)+standard pharmacotherapy (SP) patients receive SLIT as 5 sublingual droplets three times a week for 3 years (Dermatophagoides pteronyssinus and pharinea %50 mix) after following an induction phase for 1 month of slowly increasing dosing schedule reaching the maintenance dose mentioned above with the same preparation 1st dose is supervised by the physician and the rest is ingested by patient at home 2. subcutaneous immunotherapy (SCIT)+standard pharmacotherapy

1. sublingual immunotherapy (SLIT)+standard pharmacotherapy (SP) patients receive SLIT as 5 sublingual droplets three times a week for 3 years (Dermatophagoides pteronyssinus and pharinea %50 mix) after following an induction phase for 1 month of slowly increasing dosing schedule reaching the maintenance dose mentioned above with the same preparation 1st dose is supervised by the physician and the rest is ingested by patient at home 2. subcutaneous immunotherapy (SCIT)+standard pharmacotherapy SCIT is received by subcutaneous injection at the hospital by the physician once a month for 3 years (Dermatophagoides pteronyssinus and pharinea %50 mix) following a weekly injection (for 3 months) of increasing doses of allergen. a)starting dose of SCIT 0.1 ml of 100u/ml b) maintenance dose of SCIT 1 ml of 100000u/ml of allegen injected every child is supervised by a physician following the injection for half an hour

Sponsors

Marmara University BAPKO
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
5 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

to have informed consent house dust mite sensitized asthmatic/rhinitis child

Exclusion criteria

previous immunotherapy chronic disease malignancy uncontrolled asthma

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026